Patient demographics and characteristics in the extension study per survival outcome.
| Characteristic | 53 Survivors* | 44 Deaths |
|---|---|---|
| Age, yrs, median (range) | 56.8 (23–77) | 56.8 (31–78) |
| Sex (%) | ||
| Female | 48 (91) | 39 (89) |
| Male | 5 (9) | 5 (11) |
| Race (n, %) | ||
| Caucasian | 42 (79) | 41 (93) |
| African American | 4 (8) | 2 (5) |
| Hispanic | 1 (2) | 0 (0) |
| Asian | 6 (11) | 1 (2) |
| Height, cm, median (range) | 163.0 (145–187) | 164.5 (146–182) |
| Weight, kg, median (range) | 73.0 (42.0–126.8) | 69.35 (38.5–95.9) |
| NYHA class (n, %) | ||
| II | 5 (9) | 0 (0) |
| III | 39 (74) | 38 (86) |
| IV | 9 (17) | 6 (14) |
| Vasodilator use (%) | ||
| No | 15 (28) | 15 (34) |
| Yes | 38 (72) | 29 (66) |
| SSD diagnosis (n, %) | ||
| Limited scleroderma | 37 (70) | 32 (73) |
| Overlap syndrome | 6 (11) | 4 (9) |
| Features of SSD | 3 (6) | 2 (5) |
| Systemic sclerosis | 7 (13) | 6 (14) |
| Scleroderma history, mo, median (range) | 46 (0–504) | 60 (2–360) |
| PAH history, mo, median (range) | 9 (1–96) | 7 (1–84) |
↵* Includes patients alive at study conclusion and patients withdrawn. NYHA: New York Heart Association; PAH: pulmonary arterial hypertension; SSD: Scleroderma spectrum of disease.